Lucane Pharma's Pheburane Receives EU Approval, Reducing Barriers to Long-Term Treatment for UCD
Key Point of 2013 EU Approval
In 2013, the European Commission approved Pheburane (sodium phenylbutyrate), developed by Lucane Pharma, as an adjunct therapy for the chronic management of urea cycle disorders (UCD). It is indicated for patients with deficiencies in carbamoyl phosphate synthetase, ornithine transcarbamylase, and argininosuccinate synthetase. Following the approval, the product was commercialized. Currently, Eurocept International B.V., a privately held company, holds the marketing authorization for the EU. In 2017, Eurocept B.V. acquired 100% of Lucane Pharma's shares. Therefore, this case should be interpreted as an example of formulation innovation that entered the rare disease market by improving the convenience of existing nitrogen-removing agents rather than introducing a new mechanism.
Mechanism of Action and Clinical Evidence
The active ingredient in Pheburane, sodium phenylbutyrate, is converted in the body to phenylacetate, which then combines with glutamine to form phenylacetylglutamine, which is excreted in the urine, thereby removing nitrogen. EMA's CHMP adopted a positive opinion on February 21, 2013, and recommended approval based on bioequivalence and comparable quality to the reference drug, Ammonaps (sodium phenylbutyrate). The coated granules are designed to reduce the exposure to the bitter taste of the drug before it dissolves, but this should be distinguished from the results that demonstrated the superiority of ammonia-lowering efficacy. The FDA also approved the oral pellet formulation on June 17, 2022, after reviewing NDA 216513 without a separate clinical trial to demonstrate superiority or an advisory committee (AdComm) vote.
Competitive Landscape and Market Potential
The direct competitors are Ammonaps, Buphenyl, Olpruva (approved by the FDA in 2022), and Ravicti, a glycerol phenylbutyrate formulation. Ravicti is a tasteless, odorless liquid formulation with high compliance, and Horizon Therapeutics reported net sales of USD 325.6 million in 2022, providing a clear commercial benchmark. Cognitive Market Research estimates the global UCD treatment market at USD 568.21 million in 2025, and Technavio estimates the glycerol phenylbutyrate segment alone at USD 436.02 million in 2024. The opportunity for Pheburane lies in reducing the taste and administration burden for patients who require lifelong treatment and in providing payers with more options for the same active ingredient.
Investment and Business Development Implications
The EMA approval provided a regulatory basis for sales throughout Europe, and with the subsequent US approval, Pheburane has become a commercializable rare metabolic disease asset in Europe and North America. However, as it is a product based on bioequivalence, price, insurance coverage, access to specialty pharmacies, and patient retention will determine sales. Given the strong brand presence of Ravicti and the existence of several other nitrogen-removing agents such as Ammonaps, Buphenyl, and Olpruva, it is difficult to consider it as a unique growth asset. Considering the private structure of Eurocept and the fact that the 2017 acquisition price was not disclosed, the investment focus is on expanding distribution by country and actual prescription conversion data rather than re-evaluating corporate value.
Pheburane is a marketed rare disease treatment that has received EU approval in 2013 and FDA approval in 2022. It uses coated granules to reduce the bitter taste and administration burden compared to the same active ingredient, Ammonaps and Buphenyl. The global UCD treatment market is estimated at USD 568.21 million in 2025, and the competing drug Ravicti recorded net sales of USD 325.6 million in 2022, capturing a significant portion of the market. Short-term performance will depend on the expansion of European coverage and the prescription conversion rate in the US specialty distribution network, while in the medium to long term, price competition from Olpruva and generic sodium phenylbutyrate will put pressure on margins. For researchers and the industry, it is an example of how regulatory and commercial value can be created through bioequivalence and formulation improvements without discovering new targets, but compliance and accessibility are the key differentiators rather than efficacy superiority.
Source: EMA (ema)